Related references
Note: Only part of the references are listed.Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes
Rita Basu et al.
DIABETES (2008)
Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells involvement of PPAR-α
Shucun Qin et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
The effect of insulin on net lipid oxidation predicts worsening of insulin resistance and development of type 2 diabetes mellitus
Juraj Koska et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Incidence of coronary heart disease in type 2 diabetic men and women - Impact of microvascular complications, treatment, and geographic location
Angelo Avogaro et al.
DIABETES CARE (2007)
Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes
T. Cadoudal et al.
DIABETOLOGIA (2007)
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes
A. Gastaldelli et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effects of pioglitazone on lipid and lipoprotein metabolism
D. John Betteridge
DIABETES OBESITY & METABOLISM (2007)
Overproduction of large VLDL particles is driven by increased liver fat content in man
M Adiels et al.
DIABETOLOGIA (2006)
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
K Al Majali et al.
DIABETOLOGIA (2006)
Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes:: A double-blind, randomized study with metformin
APM Viljanen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes -: A positron-emitting tomography study
KA Virtanen et al.
DIABETES (2005)
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
K Nagashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes
JPH Van Wijk et al.
DIABETES CARE (2005)
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes
GD Tan et al.
DIABETOLOGIA (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo
I Bogacka et al.
DIABETES CARE (2004)
Fasting and daylong triglycerides in obesity with and without type 2 diabetes
JPH van Wijk et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
A futile cycle induced by thiazolidinediones in human adipose tissue?
GD Tan et al.
NATURE MEDICINE (2003)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
A futile metabolic cycle activated in adipocytes by antidiabetic agents
HP Guan et al.
NATURE MEDICINE (2002)
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
AB Mayerson et al.
DIABETES (2002)
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
ND Oakes et al.
DIABETES (2001)
Fuel selection in human skeletal muscle in insulin resistance - A reexamination
DE Kelley et al.
DIABETES (2000)